The Fly | ONCY

Unique Dual Mechanism of Action: Pelareorep is a proprietary, intravenously delivered oncolytic reovirus that directly lyses cancer cells while simultaneously stimulating a robust anti-cancer immune response, offering a distinct approach from conventional therapies.

Synergistic Immunooncology Potential: Its ability to enhance anti-tumor immunity and "turn cold tumors hot" makes it highly complementary to checkpoint inhibitors and other immunotherapies, potentially improving outcomes in difficult-to-treat cancers.

Broad Tumor Type Applicability: Clinical trials are ongoing or completed across multiple solid tumor types (e.g., breast, pancreatic, colorectal) and hematological malignancies, demonstrating its wide potential utility.

Clinical Trial Failure Risks: Pelareorep's ongoing and future clinical trials may not demonstrate sufficient efficacy or safety to meet regulatory endpoints, leading to disapproval, delays, or termination of development programs.

Regulatory Approval Hurdles: The company faces significant challenges in obtaining necessary regulatory approvals for pelareorep in various jurisdictions, which could be denied, delayed, or subject to burdensome conditions and post-market requirements.

Capital Requirements and Dilution: Oncolytics Biotech is a development-stage company that requires substantial additional funding to complete clinical trials and commercialization, potentially leading to significant shareholder dilution through future equity offerings.